Table 1.
1. Choice of induction and maintenance agent (since rituximab associates with higher risk of COVID) |
2. Use of corticosteroids for induction in a patient with concomitant ANCA vasculitis flare and COVID-19 |
3. Testing for COVID-19 routinely in patients with vasculitic flares in the absence of clinical symptoms for COVID-19 |